Drug
Penpulimab clinical trials
Also written AK105.
- studies test it
- 58
- open now
- 23
- in phase 3
- 7
- first study started
- 2018
Keep track of what changes. Save the penpulimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- AK105
- 17
Studies by the year they started
58 studies that test it; most in 2022 (18)
| Year | Studies |
|---|---|
| 2018 | 5 |
| 2019 | 2 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 18 |
| 2023 | 11 |
| 2024 | 5 |
| 2025 | 3 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 15
- Phase 2
- 39
- Phase 3
- 7
- Phase 4
- 1
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 27 · Other 31
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (16) · Akeso (8) · Peking Union Medical College Hospital (5) · The First Affiliated Hospital with Nanjing Medical University (4) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (3) · The First Affiliated Hospital of Zhengzhou University (2) · Hunan Cancer Hospital (2) · West China Hospital (2)
Often tested with
Tested in the same studies.
Anlotinib (13) · Catequentinib hydrochloride (13) · Anti-TIM-3 Monoclonal Antibody TQB2618 (4) · Paclitaxel (4) · Gemcitabine (3) · Oxaliplatin (3) · Albumin-Bound Paclitaxel (2) · Disitamab vedotin (2)
Studies
Open first, then newest update. How each study uses penpulimab is read from its arms, and is right about nine times in ten.
Testing it · 58
- R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNot applicableWEI XUNCT07764601Written as Penpulimab
- Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07612098Written as Penpulimab
- Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort CRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06821503Written as Penpulimab injection
- Clinical Studies for the Treatment of Advanced Solid TumorsRecruitingPhase 1/2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06825494Written as LM-108 injection+Penpulimab+ Oxaliplatin+Capecitabine
- SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal CancerRecruitingPhase 2Ruijin HospitalNCT05576480Written as Penpulimab
- A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal AdenocarcinomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767800Written as TQB2102 for injection (6 mg/7.5 mg) +Penpulimab+Chemotherapy
- JDB153 Combined With Penpulimab for Hepatocellular Carcinoma After Standard Treatment FailureNot yet recruitingPhase 1/2West China HospitalNCT07075419Written as Penpulimab
- Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell CarcinomaRecruitingPhase 2Nanfang Hospital, Southern Medical UniversityNCT05214222Written as Anlotinib/Penpulimab/Chemotherapy
- Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRCRecruitingPhase 2Fudan UniversityNCT05229003Written as Penpulimab
- TQB2223 Injection in Combination With Penpulimab in Patients With Advanced CancersRecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05894421Written as TQB2223 injection+ Penpulimab Injection
- Piamprilizumab (AK105) Combined With Radiotherapy for Neoadjuvant Treatment of Soft Tissue SarcomaRecruitingNot applicableHenan Cancer HospitalNCT05718778Written as Piamprimab (AK105)
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06010901Written as Penpulimab injection
- A Phase II Study of Anlotinib Combined With Penpulimab in Subjects With Gynecological CancerRecruitingPhase 2Sichuan Cancer Hospital and Research InstituteNCT05028504Written as Penpulimab
- XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05494060Written as Penpulimab Injection
- Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid CancerNot yet recruitingNot applicablePeking Union Medical College HospitalNCT06062563Written as Anlotinib Hydrochloride Capsule and Penpulimab
- Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic CancerRecruitingPhase 2The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT06051851Written as Penpulimab
- The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingPhase 2Peking Union Medical College HospitalNCT05885399Written as Penpulimab
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05862337Written as Anlotinib hydrochloride capsules, Penpulimab injection
- A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial CarcinomaNot yet recruitingPhase 4Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT05488353Written as Disitamab Vedotin for Injection,Penpulimab Injection
- Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT05347641Written as Penpulimab
See all 58 studies that test penpulimab →
Given in every arm · 3 — penpulimab is usual care beside what is tested
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT06516978Written as Penpulimab
- A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal CarcinomaCompletedPhase 2AkesoNCT04736810Written as AK105
- A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid TumorStatus unknownPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04291248Written as AK105
As the comparator · 2 — what is tested is compared with penpulimab
Codes
What other systems call penpulimab · ClinicalTrials.gg INT001779
- MeSH (NLM) C000720860penpulimabOne source NLM
- UNII (FDA) IBS1BZ4E4IPENPULIMABConfirmed FDA, NLM
- NCI Thesaurus C155879PenpulimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000720860 | penpulimab | One source NLM |
| UNII (FDA) | IBS1BZ4E4I | PENPULIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C155879 | Penpulimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.